JP2013540725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540725A5 JP2013540725A5 JP2013527497A JP2013527497A JP2013540725A5 JP 2013540725 A5 JP2013540725 A5 JP 2013540725A5 JP 2013527497 A JP2013527497 A JP 2013527497A JP 2013527497 A JP2013527497 A JP 2013527497A JP 2013540725 A5 JP2013540725 A5 JP 2013540725A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- nucleic acid
- acid molecule
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 50
- 239000002773 nucleotide Substances 0.000 claims 44
- 125000003729 nucleotide group Chemical group 0.000 claims 44
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 30
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 30
- 102000039446 nucleic acids Human genes 0.000 claims 30
- 108020004707 nucleic acids Proteins 0.000 claims 30
- 238000011282 treatment Methods 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 28
- 201000010099 disease Diseases 0.000 claims 25
- 208000035475 disorder Diseases 0.000 claims 25
- 239000013543 active substance Substances 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- 230000002265 prevention Effects 0.000 claims 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 10
- 201000005787 hematologic cancer Diseases 0.000 claims 10
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 206010038389 Renal cancer Diseases 0.000 claims 5
- 229930013930 alkaloid Natural products 0.000 claims 5
- 229940100198 alkylating agent Drugs 0.000 claims 5
- 239000002168 alkylating agent Substances 0.000 claims 5
- 230000000340 anti-metabolite Effects 0.000 claims 5
- 229940100197 antimetabolite Drugs 0.000 claims 5
- 239000002256 antimetabolite Substances 0.000 claims 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 5
- 229960001467 bortezomib Drugs 0.000 claims 5
- 238000002659 cell therapy Methods 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229960003957 dexamethasone Drugs 0.000 claims 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 5
- 229960002949 fluorouracil Drugs 0.000 claims 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 5
- 235000008191 folinic acid Nutrition 0.000 claims 5
- 239000011672 folinic acid Substances 0.000 claims 5
- 208000005017 glioblastoma Diseases 0.000 claims 5
- 201000010982 kidney cancer Diseases 0.000 claims 5
- 229960004942 lenalidomide Drugs 0.000 claims 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 5
- 229960001691 leucovorin Drugs 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 229960000485 methotrexate Drugs 0.000 claims 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 229960004618 prednisone Drugs 0.000 claims 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 5
- 229960003787 sorafenib Drugs 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 229960001603 tamoxifen Drugs 0.000 claims 5
- 150000003505 terpenes Chemical class 0.000 claims 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 4
- 229960004528 vincristine Drugs 0.000 claims 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 3
- 238000009098 adjuvant therapy Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10009397 | 2010-09-09 | ||
| EP10009397.0 | 2010-09-09 | ||
| PCT/EP2011/004554 WO2012031773A1 (en) | 2010-09-09 | 2011-09-09 | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540725A JP2013540725A (ja) | 2013-11-07 |
| JP2013540725A5 true JP2013540725A5 (enExample) | 2014-10-30 |
| JP6243736B2 JP6243736B2 (ja) | 2017-12-06 |
Family
ID=44653255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527497A Active JP6243736B2 (ja) | 2010-09-09 | 2011-09-09 | Ｓｄｆ−１結合核酸および癌治療におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20130310442A1 (enExample) |
| EP (1) | EP2613789B1 (enExample) |
| JP (1) | JP6243736B2 (enExample) |
| KR (1) | KR101937939B1 (enExample) |
| CN (1) | CN103108641B (enExample) |
| AU (1) | AU2011300818B2 (enExample) |
| BR (1) | BR112013005664B8 (enExample) |
| CA (1) | CA2810950C (enExample) |
| DK (1) | DK2613789T3 (enExample) |
| ES (1) | ES2678497T3 (enExample) |
| MX (1) | MX357770B (enExample) |
| RU (1) | RU2679495C2 (enExample) |
| SG (2) | SG188220A1 (enExample) |
| WO (1) | WO2012031773A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG188220A1 (en) * | 2010-09-09 | 2013-04-30 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
| WO2017178119A1 (en) * | 2016-04-15 | 2017-10-19 | Noxxon Pharma Ag | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| DE69932510T2 (de) | 1998-03-24 | 2007-02-15 | Chugai Seiyaku K.K. | Vaskularisierungsinhibitoren |
| EP2308996A1 (en) * | 1998-03-30 | 2011-04-13 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| WO2002000233A2 (en) * | 2000-06-26 | 2002-01-03 | Wellstat Biologics Corporation | Purging of cells using viruses |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| US20060019917A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| ATE347695T1 (de) | 2001-06-07 | 2006-12-15 | Chemocentryx Inc | Zellwanderungsassay |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| EP1438321B1 (de) | 2001-10-26 | 2010-05-26 | Noxxon Pharma AG | Modifizierte l-nukleinsäure |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| EP1608318A4 (en) * | 2003-03-27 | 2009-07-29 | Univ Emory | CXCR4 ANTAGONISTS AND METHOD OF USE |
| AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
| EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
| WO2006126209A1 (en) * | 2005-05-26 | 2006-11-30 | Rappaport Family Institute For Research In The Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
| US20070043012A1 (en) * | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
| JP5380287B2 (ja) * | 2006-07-18 | 2014-01-08 | ノクソン・ファルマ・アクチエンゲゼルシャフト | Ｓｄｆ−１結合核酸 |
| JP5244785B2 (ja) * | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体 |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| AU2007337983A1 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies |
| PT2190991T (pt) | 2007-08-06 | 2019-12-16 | Noxxon Pharma Ag | Ácidos nucleicos que se ligam a sdf 1 e a sua utilização |
| SG188220A1 (en) * | 2010-09-09 | 2013-04-30 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
-
2011
- 2011-09-09 SG SG2013011150A patent/SG188220A1/en unknown
- 2011-09-09 CN CN201180043233.4A patent/CN103108641B/zh active Active
- 2011-09-09 SG SG10201506725QA patent/SG10201506725QA/en unknown
- 2011-09-09 KR KR1020137006584A patent/KR101937939B1/ko active Active
- 2011-09-09 EP EP11757776.7A patent/EP2613789B1/en active Active
- 2011-09-09 WO PCT/EP2011/004554 patent/WO2012031773A1/en not_active Ceased
- 2011-09-09 AU AU2011300818A patent/AU2011300818B2/en active Active
- 2011-09-09 BR BR112013005664A patent/BR112013005664B8/pt active IP Right Grant
- 2011-09-09 JP JP2013527497A patent/JP6243736B2/ja active Active
- 2011-09-09 US US13/821,669 patent/US20130310442A1/en not_active Abandoned
- 2011-09-09 DK DK11757776.7T patent/DK2613789T3/en active
- 2011-09-09 CA CA2810950A patent/CA2810950C/en active Active
- 2011-09-09 MX MX2013002722A patent/MX357770B/es active IP Right Grant
- 2011-09-09 ES ES11757776.7T patent/ES2678497T3/es active Active
- 2011-09-09 RU RU2013115739A patent/RU2679495C2/ru active
-
2015
- 2015-11-20 US US14/947,173 patent/US9387221B2/en active Active
-
2016
- 2016-07-03 US US15/201,477 patent/US10093934B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7578643B2 (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| CN108289892B (zh) | 治疗组合物、组合和使用方法 | |
| CN114761012B (zh) | 组合疗法 | |
| KR102945599B1 (ko) | 암 치료를 위한 ch5126766과 조합된 vs-6063 | |
| JP2012067116A5 (enExample) | ||
| WO2020185532A1 (en) | Methods of treating cancer with an fgfr inhibitor | |
| CN115279376A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| JP2008507536A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| JP2016530280A5 (enExample) | ||
| CN109310677A (zh) | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| KR20240041978A (ko) | 비정상적 세포 성장을 치료하기 위한 조합 요법 | |
| JP2016519684A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2013537552A5 (ja) | ジアンヒドロガラクチトール及びジアセチルジアンヒドロガラクチトール等の置換ヘキシトールを含む準最適に投与された化合物の治療的有効性を改良するための組成物及び置換ヘキシトールを含む薬剤を調製するための方法 | |
| JP2016520622A5 (enExample) | ||
| JP2024513575A (ja) | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2018503610A5 (enExample) | ||
| JP2024542248A (ja) | Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法 | |
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| JP2025163103A (ja) | 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用 |